Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Core Viewpoint - AVITA Medical, Inc. is under investigation for potential violations of federal securities laws following a significant backlog in unpaid provider claims for its Recell procedures, which negatively impacted the company's financial performance and stock price [1][2]. Financial Performance - On August 7, 2025, AVITA reported its second quarter 2025 financial results, indicating a six-month backlog in unpaid provider claims for Recell procedures, which affected first-half demand [2]. - The backlog was attributed to contractors from the Centers for Medicare & Medicaid Services failing to assign adequate pricing and timely adjudication of claims, leading to uncertainty among providers and reduced utilization of Recell [2]. - Following the announcement, AVITA's stock price dropped by $1.13, or 21%, closing at $4.25 per share on August 8, 2025, resulting in financial harm to investors [2].